Microvillus Length Biomarker for Inflammatory Bowel Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel disease (IBD) lack objective criteria for selecting therapies, leading to a trial-and-error approach that is inefficient and potentially ineffective.
Innovation Solution
Assessing microvillus length in a biological sample to predict responsiveness to anti-inflammatory bowel disease treatments such as anti-IL-12/23, anti-α4β7 integrin, and anti-TNFα therapies, using microvillus length as a mucosal marker to determine suitable treatments for IBD patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If a stepwise approach to medication is used to treat IBD, then patient safety is improved by using less harmful drugs first, but treatment efficiency deteriorates due to the trial-and-error process
Solution Approach 1:
The patent applies preliminary action by measuring microvillus length before initiating IBD treatment to predict patient responsiveness in advance. This allows clinicians to pre-select the most appropriate therapy (anti-TNFα, anti-IL-12/23, or anti-α4β7 integrin) based on the biomarker, avoiding the traditional stepwise trial-and-error approach and improving treatment efficiency while maintaining safety.
2Adaptability or versatility
If no objective criteria are used for selecting IBD therapy, then treatment flexibility is maintained, but therapeutic effectiveness deteriorates due to lack of guidance
Solution Approach 1:
The patent applies local quality by using microvillus length as a specific biomarker that provides localized information about patient responsiveness to different IBD therapies. This objective criterion enables personalized treatment selection, allowing clinicians to adapt therapy based on individual patient characteristics while maintaining overall treatment flexibility across different patient populations.
Solution Approach 2:
The patent applies parameter changes by utilizing microvillus length as a measurable parameter to guide therapy selection. By changing from subjective clinical judgment to an objective biomarker parameter, the patent improves therapeutic effectiveness while maintaining treatment adaptability through data-driven decision-making.
3Reliability
If microvillus length measurement is implemented to predict treatment responsiveness, then therapeutic effectiveness is improved, but diagnostic complexity increases
Solution Approach 1:
The patent applies mechanics substitution by replacing complex clinical trial-and-error diagnostic processes with a straightforward microvillus length measurement. This simple biomarker assessment substitutes for multiple steps of clinical evaluation, reducing diagnostic complexity while improving therapeutic effectiveness through objective treatment prediction.
Data Source
AI summary
The present disclosure provides methods of selecting a treatment for an inflammatory bowel disease in a subject. In particular, using an indicator of epithelial absorption and metabolism the present disclosure provides method for determining the likelihood a subject is responsive or non-responsive to an inflammatory bowel disease therapeutic agent. The method includes providing a baseline measurement of a microvillus length in the small intestine of a subject, selecting a treatment for the subject according to a treatment criteria, and administering the treatment to the subject.